Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance for Molecular Bladder Cancer Detection

By HospiMedica staff writers
Posted on 02 Jan 2003
An agreement to sublicense exclusive worldwide diagnostic rights to develop and commercialize an immunohistochemistry test to detect the presence of the CD52 antigen in lymph nodes has been announced by Ilex Oncology, Inc. More...
(San Antonio, TX, USA). The licensee is Ventana Medical Systems (Tucson, AZ, USA). The agreement is intended to aid the rapid commercialization of Ilex's cancer drug.

"A standardized test will accelerate the routine screening of the CD52 antigen, which, according to recent findings, appears to be associated with several types of cancer, including lymphomas, in addition to B-cell chronic lymphocytic leukemia (B-CLL). It will also serve as a valuable tool enabling Ilex clinicians to pinpoint cancers in which Campath may play a key therapeutic role.”

Campath (alemtuzumab) is used for the treatment of patients with B-CLL who have been treated with alkylating agents and failed fludarabine therapy. The drug works by targeting the CD52 antigen, resulting in the removal of malignant lymphocytes from the blood, lymph nodes, bone marrow, and other affected organs. Campath is the product of Ilex. Recently, Ilex acquired exclusive commercial rights to CD52 antigen testing from BTG International Limited.





Related Links:
Ilex
Ventana

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Immobilization System
Cranial 4Pi Immobilization
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.